Clinical Trial Update: A Phase I/II Study of Paclitaxel Plus Carboplatin Plus Vorinostat in Recurrent Ovarian Cancer [Phase 2]

View source ↗

Summary

A Phase I/II clinical trial evaluating the combination of paclitaxel, carboplatin, and vorinostat in patients with recurrent ovarian cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• PACLITAXEL (PACLITAXEL)
• Vorinostat (vorinostat)

Snippet

Sponsor: Herlev Hospital | Conditions: Ovarian Cancer | Phase 2 | Status: UNKNOWN